Amedisys, Inc. (NASDAQ:AMED – Get Rating) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,090,000 shares, a growth of 7.2% from the February 13th total of 1,950,000 shares. Based on an average daily volume of 427,600 shares, the short-interest ratio is currently 4.9 days. Currently, 6.6% of the company’s shares are short sold.
Analyst Ratings Changes
A number of analysts have weighed in on AMED shares. Royal Bank of Canada lowered their target price on Amedisys from $114.00 to $111.00 and set an “outperform” rating for the company in a report on Tuesday, February 21st. Oppenheimer decreased their price objective on Amedisys from $145.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, January 19th. Credit Suisse Group reiterated an “outperform” rating and set a $115.00 price objective on shares of Amedisys in a report on Monday, February 27th. Benchmark reiterated a “buy” rating and set a $115.00 price objective on shares of Amedisys in a report on Tuesday. Finally, Stephens reiterated an “equal weight” rating and set a $103.00 price objective on shares of Amedisys in a report on Tuesday. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $119.53.
Amedisys Price Performance
Shares of AMED opened at $77.45 on Thursday. The business’s 50-day moving average is $90.18 and its two-hundred day moving average is $94.24. The company has a market capitalization of $2.52 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 1.04. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.09 and a current ratio of 1.09. Amedisys has a fifty-two week low of $76.93 and a fifty-two week high of $179.91.
Insider Activity at Amedisys
In related news, insider Michael Paul North sold 5,908 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $86.43, for a total value of $510,628.44. Following the completion of the sale, the insider now owns 4,164 shares in the company, valued at $359,894.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is owned by company insiders.
Institutional Investors Weigh In On Amedisys
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMED. BlackRock Inc. grew its position in shares of Amedisys by 1.5% during the 3rd quarter. BlackRock Inc. now owns 3,960,416 shares of the health services provider’s stock valued at $383,327,000 after acquiring an additional 57,035 shares during the period. Vanguard Group Inc. grew its position in shares of Amedisys by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,042,027 shares of the health services provider’s stock valued at $294,438,000 after acquiring an additional 10,457 shares during the period. Wellington Management Group LLP grew its position in shares of Amedisys by 3.5% during the 1st quarter. Wellington Management Group LLP now owns 1,875,274 shares of the health services provider’s stock valued at $323,092,000 after acquiring an additional 62,863 shares during the period. JPMorgan Chase & Co. grew its position in shares of Amedisys by 3.4% during the 4th quarter. JPMorgan Chase & Co. now owns 1,759,870 shares of the health services provider’s stock valued at $147,020,000 after acquiring an additional 58,365 shares during the period. Finally, Riverbridge Partners LLC grew its position in shares of Amedisys by 8.2% during the 3rd quarter. Riverbridge Partners LLC now owns 1,628,273 shares of the health services provider’s stock valued at $157,601,000 after acquiring an additional 123,286 shares during the period. 96.17% of the stock is owned by institutional investors and hedge funds.
Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.